A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery

Tom Miller, co-founder and CEO of Iambic Therapeutics, discusses the company’s AI platform, the insights Iambic gains from using a quantum mechanics-based approach to drug discovery, and its growing pipeline of cancer therapies.